Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Dec 1;19(23):2900-11.
doi: 10.1101/gad.1366405.

Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish

Affiliations

Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish

Jun Chen et al. Genes Dev. .

Abstract

Transcription factor p53 forms a network with associated factors to regulate the cell cycle and apoptosis in response to environmental stresses. However, there is currently no direct genetic evidence to show if or how the p53 pathway functions during organogenesis. Here we present evidence to show that the zebrafish def (digestive-organ expansion factor) gene encodes a novel pan-endoderm-specific factor. A loss-of-function mutation in def confers hypoplastic digestive organs and selectively up-regulates the expression of Delta113p53, counterpart to a newly identified isoform of p53 produced by an alternative internal promoter in intron 4 of the p53 gene in human. The increased Delta113p53 expression is limited to within the mutant digestive organs, and this increase selectively induces the expression of p53-responsive genes to trigger the arrest of the cell cycle but not apoptosis, resulting in compromised organ growth in the mutant. Our data demonstrate that, while induction of expression of p53 and/or its isoforms is crucial to suppress abnormal cell growth, Delta113p53 is tightly regulated by an organ/tissue-specific factor Def, especially during organogenesis, to prevent adverse inhibition of organ/tissue growth.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The defhi429 mutant exhibits hypoplastic digestive organs. (A,B) At 5.5 dpf, the defhi429 mutant had an unabsorbed york sac and exhibited smaller liver and swimbladder and much thinner intestine as seen by dissection microscopes. The liver is outlined with green, the gut with red, the swimbladder with purple, and the york sac with yellow. (mu) Mutant; (wt) wild-type. (C,D) At 5 dpf, Phenol Red injection revealed that the defhi429 mutant had a smaller gallbladder (g) and underexpanded anterior intestine (in). The gut from anterior to posterior (left to right) is outlined with a black line. (E,F) At 5 dpf, alcian blue staining showed that the branchial arches 2-7 in the defhi429 mutant (mu) were deformed. Branchial arches 1-7 in wild type are indicated in E. (G-J) Histochemical staining of alkaline phosphatase showed that pronephric ducts (G,H) at 3 dpf and blood vessels (I,J) at 4 dpf in wild type (wt) and the defhi429 mutant (mu) were indistinguishable. (bv) Blood vessels; (pd) pronephric ducts.
Figure 2.
Figure 2.
def is required for the expansion growth of intestine, liver, and exocrine pancreas but not endocrine pancreas. (A,B)At2 dpf, whole-mount in situ hybridization using the pan-endoderm marker foxa1 showed that there were no discernible phenotypic differences between wild type (wt) and defhi429 mutant (mu). (in) Intestine; (lv) liver; (p) pancreas. (C,D) At 5 dpf, cross-sectioning showed that the columnar epithelium did form in the mutant gut (mu) but did not fold properly obviously due to greatly reduced cell number when compared with the wild type (wt). (E-H) The expression of gut-specific markers ifabp at 4 dpf (E,F) and alkaline phosphatase at 5 dpf (G,H, yellow arrows) was greatly reduced in the defhi429 mutant. (mu) Mutant; (sw) swimbladder; (wt) wild type. (I,J) At 2 dpf, whole-mount in situ hybridization using a pdx1 probe showed that the initiation and formation of pancreatic bud (p) was not affected in the defhi429 mutant (mu). (in) Intestine. (K,L) At 3 dpf, whole-mount in situ hybridization using a trypsin probe showed that the defhi429 mutant exhibited a much smaller exocrine pancreas. (M,N) In contrast, at 4 dpf, whole-mount in situ hybridization using an insulin probe showed that the endocrine pancreas had no discernible difference between the defhi429 mutant (mu) and the wild type (wt). (O,P) At 4.5 dpf, sectioning in situ hybridization using Fast Red (Roche)-labeled trypsin (for exocrine pancreas, in red) and DIG-labeled insulin (for endocrine pancreas, in purple) probes further confirmed that, when compared with the wild type (wt), the mass of the exocrine pancreas (ex) was greatly reduced while the endocrine pancreas (en) appeared normal in the defhi429 mutant (mu). The mutant epithelium (ep) was narrower and only weakly expressed ifabp (in purple). The liver (lv) in the wild type was labeled using a transferrin probe (for liver, red). (Q,R) At 2 dpf, whole-mount in situ hybridization using prox1 did not reveal a discernible difference between the defhi429 mutant (mu) and the wild type (wt). (S,T) At 4 dpf, the liver bud was obviously smaller and failed to form two lobes in the defhi429 mutant. (U,V) At 5 dpf, cross-sectioning through the esophagus (es) revealed that bile ducts and blood vessels were properly formed in the defhi429 mutant liver (mu) as in the wild-type liver (wt).
Figure 3.
Figure 3.
Viral vector insertion in the def gene caused the defhi429 mutant phenotype. (A) Schematic drawing shows the genomic DNA structure of the def gene. The viral vector was inserted in the second intron. The positions of two pairs of primers used for genotyping the mutant embryos are indicated, and their PCR products are shown in the DNA gel photos, respectively. Red arrowheads represent the primer pair for checking the viral insertion in heterozygous (+/-) or homozygous (-/-) mutants; green arrowheads for checking the wild-type gene in wild-type sibling (+/+) or heterozygous mutant (+/-). (B) Amino acid sequence alignment of Def (gi37046654) and its homologs/orthologs in human (gi7657019), mouse (gi20340985), Drosophila (gi20130323), C. elegans (gi17555844), and yeast (gi19076047). (C) Injection of def mRNA (def) rescued the defhi429 mutant phenotype, whereas injection of GFP mRNA (GFP) or mutant defstop mRNA (data not shown) failed to rescue the mutant phenotype. Embryos 3 and 4 d post-injection were used for whole-mount in situ hybridization with ifabp and trypsin probes, respectively. (mu) Mutant; (wt) wild-type.
Figure 4.
Figure 4.
def encodes a nuclear protein, and its expression is enriched in the endoderm organs. (A, top panel, lanes 2-7) RNA gel blot hybridization revealed that def had two transcribed forms that peaked at 12 hpf and 1 dpf and then gradually reduced to a lower level at 5 dpf. (Lane 9) The shorter form was more abundant in the adult liver (AL). (Lane 8) def expression is undetectable in the defhi429 mutant. (elf1a) elongation factor 1a. (B) Immunostaining using anti-Def antibody showed that Def is a nuclear-localized protein. (C-F) Whole-mount in situ hybridization using a def riboprobe to examine the expression patterns of def at 2 dpf (C), 3 dpf (D), 4 dpf (E), and 5 dpf (F). def expression was specifically enriched in the digestive organs from 3 to 5 dpf. (in) Intestine; (lv) liver; (p) pancreas; (sw) swimbladder. (G,H) Sectioning in situ hybridization showed that def expression is specifically enriched in the intestine (in), liver (lv), and exocrine pancreas (ex) but is excluded from the endocrine pancreas (en) at 3 and 4 dpf.
Figure 5.
Figure 5.
Loss of function of def selectively up-regulates the expression of Δ113p53 in the defhi429 mutant. (A) 5′-RACE reaction identified two p53 isoforms. The longer isoform corresponds to the wild-type p53 (p53) and was predominant in the wild-type embryos. The short isoform (Δ113p53) was drastically increased in the defhi429 mutant. (B) The short isoform contains 155 bp derived from intron 4 (letters in lowercase) immediately adjacent to exon 5 and encodes for an N-truncated p53 protein initiated at codon 113 of the wild-type p53. (C) RNA gel blot hybridization using probes for detecting both p53 and Δ113p53 isoforms (P1 probe, top panel), p53 only (P2 probe, second panel), and Δ113p53 only (P3 probe, third panel) showed that Δ113p53 but not p53 was selectively increased in the def-MO morphants (def-MO) and defhi429 mutant (mu), respectively, when compared with the standard control MO morphants (SC-MO) and the wild-type control (wt). (Bottom panel) 28S rRNA was used as the loading control. (D) Whole-mount in situ hybridization using the P1 probe showed that Δ113p53 expression in the defhi429 mutant (mu, right panels) was increased at 3 dpf, 4 dpf, and 5 dpf, and this increase was specifically limited to within digestive organs when compared with the expression of p53 in the wild type (left panels). (in) Intestine; (lv) liver; (p) pancreas; (sw) swimbladder. (E,F) At 4 dpf, sectioning in situ hybridization further confirmed that p53 expression was increased in the intestine (in), liver (data not shown), and exocrine pancreas (ex) but not in the endocrine pancreas (en) in the defhi429 mutant.
Figure 6.
Figure 6.
Cell proliferation-related but not proapoptotic-related p53 response genes are up-regulated in the defhi429 mutant. (A) RT-PCR analysis revealed that the p53 MO created an aberrant product with a larger size resulting from insertion of 89 bp from the intron 5. This 89-bp insertion introduced an early stop codon in the p53 mRNA. (MW) Molecular size marker; (lane 1) 0.5 mM p53 MO; (lane 2) standard control MO (SC-MO, human β-globin antisense morpholinos); (lane 3) 1.0 mM p53 MO; (red arrow) wild type p53; (black arrow) misspliced p53. (B) Injection of p53-MOspl targeting p53 mRNA rescued the mutant phenotype. Embryos 70 h post-injection were used for whole-mount in situ hybridization using a trypsin probe. (mu) Mutant; (wt) wild type. (C) Semiquantitative RT-PCR examination of expression of various p53 response genes in defhi429 mutant (mu) and the wild-type control (wt) at 3, 4, and 5 dpf, respectively. Homozygous defhi429 mutants (confirmed by lacking expression of def) had elevated levels of Δ113p53, cyclin G1, p21WAF1/CIP1, and mdm2 but unchanged levels of p53, reprimo, and bax when compared with the wild type (wt). (D) At 3 dpf, whole-mount in situ hybridization using cyclin G1, mdm2, and p21WAF1/CIP-1 probes showed that the expression of these genes was significantly and specifically increased in the digestive organs. (in) Intestine; (lv) liver; (p) pancreas.
Figure 7.
Figure 7.
The defhi429 mutant phenotype is caused by compromised cell proliferation. (A,C) BrdU labeling revealed that, at 4 dpf, the number and ratio of cells entering the G1-to-S-phase transition was significantly reduced in the digestive organs of the defhi429 mutant (mu) when compared with the wild type (wt). (Top panel) Cross-sectioning through liver (lv) and intestine (in). (Bottom panel) Cross-sectioning through pancreas and intestine (in). The BrdU incorporation ratios shown in C were obtained by counting BrdU-labeled cells versus total cells in a specific organ (e.g., liver) in sections from seven wild-type and seven mutant embryos, respectively. (en) Endocrine pancreas; (ex) exocrine pancreas. (B,D) At 3 and 4 dpf, histochemical staining using anti-phosphorylated histone 3 (anti-P-H3) revealed that the number and ratio of cells entering G2 to M phase was drastically reduced in the digestive organs of the defhi429 mutant (mu) when compared with the wild type (wt). The ratios of P-H3-positive cells shown in D were obtained by counting P-H3-positive cells versus total cells in a specific organ (e.g., liver) in sections from three wild-type and three mutant embryos, respectively.

References

    1. Armstrong, J.F., Kaufman, M.H., Harrison, D.J., and Clarke, A.R. 1995. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5: 931-936. - PubMed
    1. Ball, K.L. 1997. p21: Structure and functions associated with cyclin-CDK binding. Prog. Cell Cycle Res. 3: 125-134. - PubMed
    1. Benard, J., Douc-Rasy, S., and Ahomadegbe, J.C. 2003. TP53 family members and human cancers. Hum. Mutat. 21: 182-191. - PubMed
    1. Berghmans, S., Murphey, R.D., Wienholds, E., Neuberg, D., Kutok, J.L., Fletcher, C.D., Morris, J.P., Liu, T.X., Schulte-Merker, S., Kanki, J.P., et al. 2005. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc. Natl. Acad. Sci. 102: 407-412. - PMC - PubMed
    1. Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Xirodimas, D.P., Saville, M.K., and Lane, D.P. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes & Dev. 19: 2122-2137. - PMC - PubMed

Publication types

Substances